newsfilter
← Latest News
Business Wire·

Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting

Late-breaking oral presentation to feature Phase 3 topline data highlighting avexitide’s efficacy and safety Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced it